Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $281.35 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

roche holding ag-br (RHHBF) Snapshot

Open
$281.35
Previous Close
$281.35
Day High
$281.35
Day Low
$281.35
52 Week High
12/11/14 - $299.00
52 Week Low
03/11/15 - $256.25
Market Cap
243.8B
Average Volume 10 Days
78.2
EPS TTM
--
Shares Outstanding
160.0M
EX-Date
03/5/15
P/E TM
--
Dividend
$7.45
Dividend Yield
2.92%
Current Stock Chart for ROCHE HOLDING AG-BR (RHHBF)

roche holding ag-br (RHHBF) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Europe, North America, and Asia. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, drug metabolism disorder, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, human papillomavirus, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and west nile virus diseases. The company also provides diagnostic solutions for blood gas analysis; blood screening; cancer screening; cardiac markers; cardiovascular testing; cholesterol monitoring; coagulation monitoring, routing, and specialty testing; data management; diabetes monitoring and therapy; electrolytes analysis; emergency medicine; hemostasis; heterogeneous immunochemistry; homogenous immune assays; immunology; infectious diseases; intensive care testing; microarray; neonatal intensive care units; nucleic acid purification; PCR clinical diagnostics; pharmacogenomics; physical fitness and platelet function testing; PCR diagnostic systems; serum work area; urinalysis; and workflow solutions. In addition, it offers products for researchers, such as amplification, cell analysis, gene expression, gene knockdown, genome sequencing, microarrays, nucleic acid purification, protein analysis, PCR systems, and transfection products. The company has collaboration agreements with AmorChem, AbbVie, Xenon Pharmaceuticals, Stratos Genomics, The Garvan Institute, Cornell University, and University of Washington. The company was founded in 1896 and is headquartered in Basel, Switzerland.

88,509 Employees
Last Reported Date: 01/28/15
Founded in 1896

roche holding ag-br (RHHBF) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.3M
Chief Financial Officer and IT Officer
Total Annual Compensation: SFr.4.1M
Chief Operating Officer of Pharmaceuticals di...
Total Annual Compensation: SFr.5.0M
Chief Operating Officer of Diagnostics Divisi...
Total Annual Compensation: SFr.2.5M
General Counsel and Corporate Secretary
Total Annual Compensation: SFr.2.8M
Compensation as of Fiscal Year 2014.

roche holding ag-br (RHHBF) Key Developments

Roche Presents at NewYork BIO 25th Anniversary Conference 2015, May-04-2015 05:00 PM

Roche Presents at NewYork BIO 25th Anniversary Conference 2015, May-04-2015 05:00 PM. Venue: Time Warner Center, New York, United States. Speakers: Judy Dunn, Global Head Clinical Development.

4D Molecular Therapeutics and Roche Sign Collaboration Agreement for Gene Therapy Vector Discovery and Product Development

4D Molecular Therapeutics announced a collaboration and license agreement with Roche to discover and develop optimized next-generation AAV vectors for indications with high unmet medical need. 4DMT will deploy its proprietary AAV vector discovery platform, Directed Vector Evolution, to identify and optimize novel gene delivery vectors for use in gene therapy products. Financial details were not disclosed. This partnership was facilitated by QB3, a multi-campus University of California (including UC Berkeley & UC San Francisco) research institute and biotech accelerator, which seeks to catalyze relationships between large companies and startups at QB3’s incubators. 4D Molecular Therapeutics is based in the QB3@953 and JLABS (Johnson&Johnson Innovation) laboratories in the Mission Bay area of San Francisco.

Roche Reports Sales Results for the First Quarter of 2015; Provides Sales Guidance for the Year 2015

Roche reported sales results for the first quarter of 2015. For the quarter, the company reported 3% rise in sales despite a strong Swiss franc. Sales rose to CHF 11.8 billion from CHF 11.4 billion last year. For the year 2015, the company continues to expect sales to grow low- to mid-single digit, at constant exchange rates.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHHBF:US $281.35 USD 0.00

RHHBF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $102.27 USD -0.72
Johnson & Johnson $99.17 USD -0.33
Novartis AG SFr.91.50 CHF -1.85
Pfizer Inc $33.46 USD -0.66
Sanofi €88.09 EUR -2.35
View Industry Companies
 

Industry Analysis

RHHBF

Industry Average

Valuation RHHBF Industry Range
Price/Earnings 26.5x
Price/Sales 4.9x
Price/Book 12.4x
Price/Cash Flow 21.6x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-BR, please visit www.roche.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.